APLS: Apellis Pharmaceuticals, Inc.
About
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Current Value
$28.781 Year Return
Current Value
$28.781 Year Return
Key Details
Market Cap
$3.61B
P/E Ratio
-14.23
1Y Stock Return
-41.27%
1Y Revenue Growth
162.10%
Dividend Yield
0.00%
Price to Book
14.9
Strategies that include APLS
Stock's related to APLS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PGEN | 39.69% | $228.91M | -28.00% | 0.00% |
| ZYME | 37.54% | $1.03B | +79.68% | 0.00% |
| BCRX | 37.41% | $1.49B | +41.37% | 0.00% |
| CLPT | 34.49% | $302.60M | +84.68% | 0.00% |
| IMVT | 34.35% | $3.70B | -23.48% | 0.00% |
| ALDX | 34.26% | $294.18M | +102.46% | 0.00% |
| BATRA | 34.03% | $2.62B | +6.13% | 0.00% |
| FOLD | 33.55% | $2.84B | -11.52% | 0.00% |
| LAB | 33.07% | $562.11M | -34.35% | 0.00% |
| RCUS | 31.64% | $1.33B | +5.07% | 0.00% |
| RYTM | 31.63% | $3.69B | +79.50% | 0.00% |
| BATRK | 31.63% | $2.51B | +13.03% | 0.00% |
| AMPH | 31.50% | $2.10B | -23.00% | 0.00% |
| BTBT | 31.45% | $595.60M | +81.53% | 0.00% |
| ATNM | 31.36% | $44.30M | -67.05% | 0.00% |
| RCKT | 31.33% | $1.20B | -39.83% | 0.00% |
| SWTX | 31.17% | $2.82B | +79.34% | 0.00% |
| CHRS | 30.73% | $94.65M | -58.72% | 0.00% |
| DMRC | 30.69% | $694.39M | -2.06% | 0.00% |
| RVMD | 30.66% | $9.50B | +171.62% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FDP | -0.05% | $1.62B | +45.67% | 2.97% |
| SOHU | -0.09% | $406.50M | +43.52% | 0.00% |
| CI | -0.11% | $89.70B | +12.57% | 1.68% |
| ARC | -0.13% | $146.66M | +18.95% | 5.90% |
| MNR | 0.19% | $1.66B | -10.71% | 15.90% |
| GKOS | 0.22% | $7.95B | +129.45% | 0.00% |
| LI | 0.27% | $18.90B | -43.16% | 0.00% |
| TD | 0.28% | $97.59B | -9.20% | 5.39% |
| EBAY | -0.29% | $29.27B | +51.28% | 1.75% |
| TBRG | 0.35% | $244.47M | +52.66% | 0.00% |
| FMX | 0.35% | $19.19B | -27.82% | 4.58% |
| CARV | -0.36% | $8.48M | -8.79% | 0.00% |
| ECL | 0.42% | $69.18B | +30.92% | 0.93% |
| DB | 0.45% | $32.64B | +37.74% | 2.90% |
| NNVC | 0.47% | $19.66M | +25.69% | 0.00% |
| SPRU | 0.49% | $42.41M | -31.94% | 0.00% |
| FMC | -0.51% | $6.94B | +4.53% | 4.17% |
| AHCO | 0.51% | $1.31B | +17.07% | 0.00% |
| CLMT | 0.52% | $1.79B | +35.14% | 0.00% |
| TECK | -0.53% | $24.49B | +31.13% | 0.78% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| XOS | -15.69% | $30.51M | -57.24% | 0.00% |
| PRPO | -15.15% | $9.10M | -13.65% | 0.00% |
| FATBB | -14.21% | $81.94M | -12.91% | 11.69% |
| ASR | -13.49% | $7.56B | +26.22% | 0.00% |
| PULM | -12.89% | $19.83M | +202.98% | 0.00% |
| DMLP | -12.44% | $1.58B | +18.00% | 10.54% |
| OXBR | -10.62% | $19.05M | +178.18% | 0.00% |
| TTE | -9.87% | $138.45B | -11.95% | 5.50% |
| PAC | -9.79% | $8.16B | +31.59% | 0.00% |
| NEUE | -9.78% | $40.93M | -34.13% | 0.00% |
| HUSA | -9.62% | $16.69M | -11.56% | 0.00% |
| DADA | -9.54% | $367.07M | -63.71% | 0.00% |
| QTTB | -9.37% | $354.34M | +188.64% | 0.00% |
| NGL | -9.12% | $572.94M | +5.60% | 0.00% |
| E | -8.74% | $46.24B | -10.80% | 9.02% |
| DLB | -8.10% | $6.76B | -16.58% | 1.69% |
| CRVO | -8.03% | $83.20M | +2.86% | 0.00% |
| AMBC | -7.11% | $584.50M | -17.09% | 0.00% |
| QFIN | -6.96% | $5.09B | +95.80% | 3.47% |
| COR | -6.86% | $47.48B | +21.20% | 0.86% |
ETF's related to APLS
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 45.01% | $6.58B | 0.35% |
| RSPA | 43.91% | $273.87M | 0% |
| IBB | 42.65% | $6.66B | 0.45% |
| PTH | 40.78% | $143.31M | 0.6% |
| PBE | 38.36% | $258.53M | 0.58% |
| FTHI | 38.13% | $1.01B | 0.75% |
| XPH | 37.61% | $157.87M | 0.35% |
| FBT | 37.39% | $1.11B | 0.56% |
| FFTY | 36.48% | $67.59M | 0.8% |
| IWO | 35.63% | $12.56B | 0.24% |
| RYLD | 35.40% | $1.45B | 0.6% |
| IWC | 35.23% | $933.99M | 0.6% |
| VBK | 34.99% | $19.31B | 0.07% |
| XSW | 34.98% | $402.79M | 0.35% |
| BBH | 34.84% | $397.87M | 0.35% |
| IHE | 34.79% | $596.23M | 0.39% |
| IWP | 34.19% | $17.19B | 0.23% |
| PFUT | 34.19% | $326.69M | 0.64% |
| XHE | 33.82% | $213.41M | 0.35% |
| ARKG | 33.73% | $1.13B | 0.75% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| COMT | -0.02% | $829.06M | 0.48% |
| USCI | -0.17% | $185.47M | 1.07% |
| MUST | 0.22% | $410.00M | 0.23% |
| GSG | -0.24% | $914.42M | 0.75% |
| FMF | 0.26% | $244.61M | 0.95% |
| FTSM | 0.38% | $6.08B | 0.45% |
| LMBS | -0.40% | $4.62B | 0.64% |
| CANE | 0.41% | $17.72M | 0.29% |
| STPZ | 0.54% | $483.31M | 0.2% |
| CORN | 0.65% | $61.12M | 0.2% |
| DBE | -1.01% | $50.13M | 0.77% |
| EWH | -1.04% | $641.56M | 0.5% |
| DFNM | 1.14% | $1.40B | 0.17% |
| SHYD | 1.22% | $311.50M | 0.35% |
| KRBN | -1.27% | $242.47M | 0.85% |
| PDBC | 1.32% | $4.40B | 0.59% |
| SPTS | 1.42% | $5.71B | 0.03% |
| JUCY | 1.50% | $324.29M | 0.6% |
| STIP | 1.51% | $8.74B | 0.03% |
| JPST | 1.73% | $28.43B | 0.18% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -22.99% | $388.04M | 1.43% |
| VIXY | -21.70% | $195.31M | 0.85% |
| IBTE | -20.32% | $1.70B | 0.07% |
| TAIL | -17.08% | $67.98M | 0.59% |
| TPMN | -13.44% | $40.60M | 0.65% |
| TBIL | -12.17% | $4.38B | 0.15% |
| XHLF | -11.94% | $874.27M | 0.03% |
| XBIL | -9.37% | $637.70M | 0.15% |
| BILZ | -9.29% | $563.02M | 0.14% |
| FLRT | -8.86% | $401.26M | 0.6% |
| DBO | -7.91% | $217.57M | 0.77% |
| HIGH | -7.79% | $302.78M | 0.51% |
| KMLM | -7.78% | $353.87M | 0.9% |
| AGZD | -7.52% | $142.76M | 0.23% |
| DBA | -7.47% | $755.88M | 0.93% |
| FLMI | -7.44% | $356.19M | 0.3% |
| KCCA | -6.60% | $220.51M | 0.87% |
| SHV | -6.29% | $18.13B | 0.15% |
| ULST | -6.16% | $535.47M | 0.2% |
| USDU | -5.68% | $201.97M | 0.5% |
News
Yahoo
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApel
Yahoo
Wells Fargo lowered the firm’s price target on Apellis (APLS) to $30 from $43 and keeps an Equal Weight rating on the shares. The firm thinks Q3 was validating for its view of a slowing GA market and that Syfovre estimates need to be reset. Wells believes incrementally negative commentary on pricing and more gradual ramp to peak will continue to weigh on shares. The firm tells investors it wouldn’t step into shares here. Published first on TheFly – the ultimate source for real-time, market-movin
Yahoo
BofA lowered the firm’s price target on Apellis (APLS) to $47 from $61 and keeps a Buy rating on the shares after the company reported Q3 Syfovre revenues that came in below expectations. The firm continues to look for clarity on the size of the geographic atrophy, or GA, market, but thinks the current valuation underestimates the potential size of the opportunity and thinks the potential launch in C3G/IC-MPGN could help offset slower growth in GA, the analyst tells investors. Published first on
Yahoo
APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.
Yahoo
Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.
Yahoo
Sales of the company's top commercialized product didn't meet expectations.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.